@ARTICLE{
author={Spina Michele,...,Ristic Dusan J,...,(broj koautora 21)},
year={2015},
title={FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk},
journal={ANNALS OF ONCOLOGY},
volume={26},
number={10},
pages={2155-2161},
document_type={Article},
} 

@ARTICLE{
author={Spina Michele,...,Ristic Dusan J,...,(broj koautora 20)},
year={2014},
title={A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={32},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Spina Michele,...,Ristic Dusan J,...,(broj koautora 25)},
year={2014},
title={Prophylaxis with Febuxostat in Comparison to Allopurinol Reduces Exposure to Uric Acid in Patients at Intermediate to High Risk of Tumor Lysis Syndrome: Results of the Florence Study},
journal={HAEMATOLOGICA},
volume={99},
number={},
pages={197-198},
document_type={Meeting Abstract},
}